March 2009
[KU 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
Branch IX – RADIO THERAPY
(Candidates admitted upto 2007-2008)
Paper IV – CANCER CHEMOTHERAPY AND RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY
AND RADIOTHERAPY
Q.P. Code : 202038
Time : Three hours Maximum : 100 marks
Draw suitable diagram wherever necessary
Answer ALL questions
I. Essay questions : (2 x 20 = 40)
1 What are the complications of chemotherapy? How will you manage a
case of neutropenic fever?
2. Write a note on Targeted molecular therapy in oncology. Give one
example with its role along with radiation.
II. Write short notes on : (10 X 6 = 60)
1. Paclitaxel.
2. Antioxidants.
3. Clinical trials.
4. Anterior chemotherapy.
5. Mode, mean and median.
6. Dose volume histogram.
7. Partial breast irradiation.
8. Quality of life.
9. PET – CT scan.
10. Gemcitalin.
*****
September 2009
[KV 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
Branch IX – RADIO THERAPY
(Candidates admitted upto 2007-2008)
Paper IV – CANCER CHEMOTHERAPY AND RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY
AND RADIOTHERAPY
Q.P. Code : 202038
Time : Three hours Maximum : 100 marks
Draw suitable diagram wherever necessary
Answer ALL questions
I. Essay questions : (2 x 20 = 40)
1. Classify various chemotherapeutic agents. Discuss Neoadjuvant
chemotherapy.
2. Discuss adjuvant chemotherapy in breast cancer.
II. Write short notes on : (10 X 6 = 60)
1. Temozolamide
2. CEA
3. Immunohistochemistry
4. Febrile neutropenia
5. Cyber knife
6. Cancer genetics
7. Virtual simulation
8. Concurrent chemoradiation in cancer cervix.
9. Parameters in descriptive statistics
10. Tumour lysis syndrome
*****
March 2010
[KW 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
Branch IX – RADIO THERAPY
Paper IV – (for candidates admitted upto 2007-2008) and
Part II / Paper III – (for candidates admitted from 2008-2009 onwards)
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code : 202038
Time : Three hours Maximum : 100 marks
Draw suitable diagram wherever necessary
Answer ALL questions
I. Essay questions : (2 x 20 = 40)
1. The role of chemotherapy in curative treatment of head and neck
cancers – Discuss.
2. Discuss – Targeted therapies.
II. Write short notes on : (10 x 6 = 60)
1. Tumour lysis syndrome
2. Temozolamide
3. Antioxidants.
4. Multileaf collimator.
5. Herceptin.
6. 5- HT3 receptor antagonist.
7. Cyclotron.
8. Performance status.
9. LQ model.
10. Fine needle aspiration cytology.
*****
Septembr 2010
[KX 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
Branch IX – RADIO THERAPY
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN
CLINICAL ONCOLOGY AND RADIOTHERAPY
Paper IV – (for candidates admitted upto 2007-2008) and
Part II - Paper III - (for candidates admitted from 2008-2009 onwards)
Q.P. Code : 202038
Time : Three hours Maximum : 100 marks
Draw suitable diagram wherever necessary.
Answer ALL questions.
I. Essay questions : (2 X 20 = 40)
1. The role of chemotherapy in the management of Non-Hodgkins
Lymphoma.
2. Discuss adjuvant chemotherapy in breast cancer.
II. Write short notes on : (10 X 6 = 60)
1. IMRT Programme.
2. Stereotactic Radiotherapy.
3. Cyber Knife.
4. Bone marrow transplantation.
5. Role of PET-CT in Radiotherapy.
6. 5- HT3 receptor antagonist.
7. National cancer control programme.
8. Clinical Trials.
9. Febrile neutropenia.
10. Cancer genetics.
*****
MAY 2011
[KY 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code : 202038
Time : 3 hours Maximum : 100 marks
(180 Min)
Answer ALL questions in the same order.
I. Elaborate on : Pages Time Marks
(Max.) (Max.) (Max.)
1. Discuss the role of chemotherapy and recent advances in
the management of locally advanced breast cancer. 11 35 15
2. Discuss Molecular genetics and targeted therapy for brain
tumours. 11 35 15
II. Write notes on :
1. Image Guided Radiation Therapy. 4 10 7
2. Role of radiotherapy in malignant melanoma. 4 10 7
3. Carcinoid syndrome. 4 10 7
4. Medulloblastoma management. 4 10 7
5. Chemoprevention. 4 10 7
6. Triple negative Breast cancer. 4 10 7
7. Role of radiotherapy in carcinoma pancreas. 4 10 7
8. Neutron Beam Therapy. 4 10 7
9. New targeted therapies for metastatic bone disease. 4 10 7
10. Management of Osteosarcoma. 4 10 7
*******
October 2011
[KZ 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code : 202038
Time : 3 hours Maximum : 100 marks
(180 Min)
Answer ALL questions in the same order.
I. Elaborate on : Pages Time Marks
(Max.) (Max.) (Max.)
1. Describe in detail the role of molecular targeted therapy
in oncological practice. 11 35 15
2. Describe the role of chemo radiation in Hodgkin’s disease. 11 35 15
II. Write notes on :
1. Clinical trials. 4 10 7
2. Molecular genetics. 4 10 7
3. National cancer control programme and screening
procedures. 4 10 7
4. Management of acute and delayed emesis in chemotherapy
management. 4 10 7
5. Tumour lysis syndrome and its management. 4 10 7
6. Chemosensitive tumours and its regimens. 4 10 7
7. Cell cycle nonspecific chemotherapeutic agents. 4 10 7
8. Febrile neutropenia and management. 4 10 7
9. Stem cell therapy in various cancers. 4 10 7
10. High dose chemotherapy. 4 10 7
*******
APRIL 2012
[LA 143] Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN CLINICAL
ONCOLOGY AND RADIOTHERAPY
Q.P. Code : 202038
Time : 3 hours Maximum : 100 marks
(180 Min)
Answer ALL questions in the same order.
I. Elaborate on : Pages Time Marks
(Max.) (Max.) (Max.)
1. Describe in detail the etiology, pathology, clinical feature,
imaging and multimodality management of caner rectum. 16 35 15
2. Describe in detail the etiology, pathology,
clinical features, imaging and multimodality
management of Non small cell lung cancer. 16 35 15
II. Write notes on :
1. Describe the management of Multiple myeloma. 4 10 7
2. Describe the management of Malignant fibrous
histiocytosis. 4 10 7
3. Describe Grading and radiation therapy importance
in sarcomas. 4 10 7
4. Describe the Salvage chemotherapy in Hodgkins Disease. 4 10 7
5. Describe the Autologous Stem cell transplantation and its
indications. 4 10 7
6. Describe the Primary chemotherapy indications. 4 10 7
7. Describe the Drugs acting in different phases of cell cycle. 4 10 7
8. Describe the Bortezumab and the schedules. 4 10 7
9. Describe the toxicity profile chemotherapy. 4 10 7
10. Describe the management of chemotherapy induced
nausea and vomiting. 4 10 7
*******
(LC 143) APRIL 2013 Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX-RADIO THERAPY
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN
CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P.Code: 202038
Time: Three Hours Maximum: 100 marks
I. Elaborate on: (2X15=30)
1. Discuss the role of chemotherapy in early breast cancer
2. Describe the management of Non-Hodgkin lymphoma
II. Write notes on: (10X7=70)
1.Discuss the Hormonal management of Prostate Cancer
2.Describe the Rapid Arc therapy with illustration
3.Illustrate the Dose Volume Histogram and its applications
4.Describe the Biologically adapted Radiation therapy
5.Describe the Management of Mucosal Reactions with Chemo and RT
6.Describe the Helical Tomotherapy with illustration
7.Describe the role of Chemoprevention
8.Describe the role of Lapatinib in cancer breast
9.Describe the K.ras Mutation
10.Describe the management of Small Cell Lung Cancer limited stage
******
(LE 143) APRIL 2014 Sub. Code:2038
M.D. DEGREE EXAMINATION
BRANCH IX - RADIO THERAPY
CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN
CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P.Code: 202038
Time: Three Hours Maximum: 100 marks
I. Elaborate on: (2X15=30)
1. Describe the role of Neoadjuvant preoperative and post operative
Radiation therapy in various tumors.
2. Describe the rationale, basis, clinical applications and its outcome of
Multimodality management of cancer.
II. Write notes on: (10X7=70)
1. Describe the Brain Sarcomas.
2. Describe the management of Neuroblastomas.
3. Describe the Gastrointestinal stromal tumors.
4. Describe the Role of metastectomy in various tumors.
5. Describe the Role of RT in recurrent Brain Tumors.
6. Describe the role of oral chemotherapeutic agents.
7. Describe the management of small Cell Lung Caner.
8. Describe Choroidal and leptomeningeal metastasis.
9. Describe the management of Chordomas.
10. Describe the Radiotherapy role in metastatic diseases.
*******
[LG 143] APRIL 2015 Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P.Code: 202038
Time: Three Hours Maximum: 100 marks
Answer ALL questions
I. Elaborate on: (2 x 15 = 30)
1. Describe the role of Radiation in the management of Lymphomas.
2. Describe the management of Triple negative breast cancer.
II. Write notes on: (10 x 7 = 70)
1. Describe the role of Targeted therapy in oropharynx cancer.
2. Describe the role of Erlotinib in lung cancer.
3. Describe the management of Rhabdomyosarcoma in Paediatrics.
4. Describe the Gliadel wafers in gliomas.
5. Describe the management of muscle invasive urinary bladder cancer.
6. Describe the Endovascular Brachytherapy.
7. Describe the management of multiple brain secondaries.
8. Describe the management of post radiation recurrences in cancer cervix.
9. Role of radiation in Cancer Vulva.
10. Describe the Folfox and Folfiri regime.
*******
(LI 143) APRIL 2016 Sub. Code:2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P.Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Discuss the steps involved in 3D Conformal Radiation Therapy
(3D CRT) for carcinoma of left breast.
2. Discuss various radiotherapy techniques for treatment of Pituitary
Adenoma with suitable diagram.
II. Write notes on: (10 x 7 = 70)
1. Management of carcinoma vagina FIGO stage III B.
2. Bevacizumab.
3. Carcino Embryonic Antigen (CEA).
4. WHO step ladder in pain management.
5. Biological therapy in Metastatic Renal Cell Carcinoma.
6. Discuss the rationale for hyperfractionated radiotherapy in head
and neck cancers.
7. Stereotactic Body Radiotherapy (SBRT).
8. IMRT (Intensity Modulated Radiation Therapy) and Brachytherapy.
Friends or Foes - Discuss.
9. Kimura’s Disease.
10. Role of Radiotherapy in Breast conservative surgery.
*******
(LK 143) MAY 2017 Sub. Code:2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P.Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Describe the Various methods in achieving uniform dose in radiation treatment.
2. Describe the role chemotherapy and targeted therapy in the management
of cancer breast.
II. Write notes on: (10 x 7 = 70)
1. Describe the role of radiation in the management of cancer pancreas.
2. Bisphosphonates.
3. Describe the management of parameningeal rhabdomyosarcoma.
4. Autologus bone marrow transplantation.
5. Describe the management of high risk Medulloblastoma.
6. Describe the Salvage chemotherapy in Testicular tumors.
7. Describe the management of T2N1M0-small cell carcinoma lung.
8. Tomotherapy.
9. Describe the role of PET scan in Lymphomas.
10. Management of primary CNS germ cell tumors.
*******
[LM 143] MAY 2018 Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P.Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Describe the role of Targeted therapy in the management of malignancy.
2. Describe the role of Chemoradiation in the management of Head and
Neck Malignancy.
II. Write notes on: (10 x 7 = 70)
1. Describe the recent advances in precision rediction.
2. Bendamustine.
3. Fertility Preservation.
4. Describe the treatment of high grade gliomas.
5. Describe the Accelerated partial Breast Radiation.
6. Describe the role of Radiation in Organ Preservation.
7. Describe the cancer vaccines.
8. Multileaf collimators.
9. Describe the management of Febrile Neutropenia.
10. Cyber knife.
*******
[LO 143] MAY 2019 Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Etiology, signs and symptoms, management of stage 3 nasopharyngeal
carcinoma. Role of IMRT in nasopharyngeal carcinoma.
2. Epidemiology, staging and prognostic factors in carcinoma cervix.
Describe in detail conventional and advanced treatment technique in
carcinoma stage IIIB.
II. Write notes on: (10 x 7 = 70)
1. Organ preservation in cancer larynx.
2. Carcinoma in-situ; ductal or lobular in breast –management.
3. Particle beam therapy.
4. Tyrosine kinase inhibitors.
5. Management of metastatic prostate cancer.
6. Management of recurrent pleomorphic adenoma.
7. Gemcitabine.
8. Radiation proctitis.
9. Immunotherapy in clinical practice.
10. Radioactive iodine therapy.
*******
[LQ 143] AUGUST 2020 Sub. Code: 2038
(MAY 2020 SESSION)
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Give an account of the predisposing factors and diagnostic evaluation of
hepatocellular carcinoma. Discuss in detail treatment modalities available for
hepatocellular carcinoma
2. Define SBRT (Stereotactic Body Radiotherapy). List the indications. Discuss
the role of SBRT in lung cancer.
II. Write notes on: (10 x 7 = 70)
1. Indications of Total Body Irradiation (TBI). Discuss the technique, dose and
precautions to be taken while planning TBI.
2. Discuss Stereotactic RadioSurgery (SRS) treatment for AV malformation with
special mention of its radiobiological basis.
3. Metronomic chemotherapy
4. Tomotherapy
5. Optimum duration of hormonal therapy in hormone positive breast cancer with
evidence
6. Infectious etiology for cancer
7. Role of PET in Lung cancer
8. Personalised radiation therapy
9. Management of CNS Lymphoma
10. Surface mould
*****
[LS 143] NOVEMBER 2020 Sub. Code: 2038
(OCTOBER 2020 SESSION)
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Discuss the role and technique of permanent interstitial brachytherapy and IMRT
(Intensity Modulated Radiation Therapy) in carcinoma prostate.
2. Discuss the rationale in combining irradiation with chemotherapy in oncological
practice.
II. Write notes on: (10 x 7 = 70)
1. Vaccines in carcinoma cervix
2. List the levels of evidence. What is meta-analysis? Explain meta-analysis with an
example.
3. Describe how to evaluate the radiotherapy plan generated with respect to Dose
Volume Histogram (DVH) and other biological indices.
4. What is immunohistochemistry? Write its role in classifying brain tumours.
5. Adaptive radiotherapy – definition, indications and its benefits.
6. Role of PET in Gynaecological malignancies.
7. Antiangiogenesis agents
8. Fertility preservation in Oncology
9. Chemotherapy regimens used for Non-Hodgkin’s Lymphoma. Mention the
prechemotherapy investigations necessary along with rationale for doing them.
10. Compare and contrast Proton and Carbon Ion therapy.
*****
[MD 0721] JULY 2021 Sub. Code: 2038
(MAY 2021 SESSION)
M.D. DEGREE EXAMINATION
BRANCH IX – RADIATION ONCOLOGY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Describe motion management in radiotherapy planning.
2. Nanotechnology in cancer management – diagnostic and therapeutic.
II. Write notes on: (10 x 7 = 70)
1. Discuss plan evaluation and QA in SRS.
2. Promises and challenges of proton therapy.
3. QANTEC – Clinical application.
4. Carbon ion therapy.
5. Tumour tracking.
6. Palbociclib.
7. Sentinel lymph node.
8. Discuss different methods of adaptive radiotherapy.
9. PET scan in treatment planning.
10. Neoadjuvant chemotherapy in carcinoma stomach.
*****
THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY
[MD 0522] MAY 2022 Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIATION ONCOLOGY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Classification of Cancer Chemotherapy agents. Mechanism of action,
pharmacokinetics and side effects of Paclitaxel.
2. Image guided Brachytherapy in Carcinoma Cervix and GEC ESTRO
recommendations.
II. Write notes on: (10 x 7 = 70)
1. Contact Brachytherapy.
2. PET CT in Oncology.
3. Nivolumab.
4. Radio Frequency Ablation (RFA).
5. Monoclonal antibodies in cancer therapy.
6. Tumor Lysis Syndrome.
7. AIDS related malignancy.
8. Sexual dysfunction in Cancer therapy.
9. Role of MRI in treatment planning.
10. Micro Satellite Instability ( MSI).
*****
THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY
[MD 1022] OCTOBER 2022 Sub. Code: 2038
M.D. DEGREE EXAMINATION
BRANCH IX – RADIATION ONCOLOGY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Classification of Hodgkin lymphoma and discuss management of stage-II HL.
2. Discuss the management of commonest Carcinoma of lung in 40 years old
smoker diagnosed to have stage-II.
II. Write notes on: (10 x 7 = 70)
1. Hormone therapy in Breast Cancer.
2. Paraneoplastic Syndromes.
3. Use of Lasers in oncology.
4. G-CSF, GM –CSF and Erythropoietin.
5. Discuss various Antiemetics used in Cancer treatment.
6. ICRU -50, 62, 83.
7. Organ preservation in cancer larynx.
8. Surface mould.
9. Describe Bortezomib and the schedules.
10. Chemoprevention.
*****
THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY
[MD 0723] JULY 2023 Sub. Code: 2038
(MAY 2023 EXAM SESSION)
M.D. DEGREE EXAMINATION
BRANCH IX – RADIO THERAPY
BRANCH XXVI - RADIATION ONCOLOGY
PAPER IV – CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS
IN CLINICAL ONCOLOGY AND RADIOTHERAPY
Q.P. Code: 202038
Time: Three Hours Maximum: 100 Marks
I. Elaborate on: (2 x 15 = 30)
1. Discuss in detail regarding monoclonal antibodies in cancer management.
2. Discuss in detail about Stereotactic Ablative Body Radiation (SABR) and its
clinical applications.
II. Write notes on: (10 x 7 = 70)
1. Hormonal therapy for prostate cancers.
2. Chemotherapy for Ewing’s sarcoma.
3. Compare and contrast IMRT, VMRT and Proton therapy.
4. Systemic therapy for triple negative breast cancers.
5. Management of Febrile Neutropenia.
6. Surface Guided Radiotherapy (SGRT).
7. Proton therapy.
8. Total Skin Electron Therapy (TSET).
9. Short course Radiotherapy in rectal cancers.
10. Diagnostic work up for Lymphomas.
*********
